Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Blood Advances|August 26, 2020
Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agentsLindsey E Roeker, Peter Dreger, Jennifer R Brown, et al.
The Lancet. Oncology|July 10, 2022
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trialConstantine S Tam, Jennifer R Brown, Brad S Kahl, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 19, 2023
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International StudyMazyar Shadman, Beenish S Manzoor, Kavita Sail, et al.
Blood|December 1, 2020
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapyAnthony R Mato, Nilanjan Ghosh, Stephen J Schuster, et al.
Blood Advances|February 15, 2024
Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosisGeffen Kleinstern, Nicholas J Boddicker, Daniel R O'Brien, et al.
Blood|January 29, 2021
Natural history of monoclonal B-cell lymphocytosis among relatives in CLL familiesSusan L Slager, Mark C Lanasa, Gerald E Marti, et al.
The New England Journal of Medicine|December 4, 2018
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLJennifer A Woyach, Amy S Ruppert, Nyla A Heerema, et al.
American Journal of Hematology|August 23, 2018
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trialAnthony R Mato, Lindsey E Roeker, John N Allan, et al.
Blood|January 12, 2024
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLLJennifer A Woyach, Gabriela Perez Burbano, Amy S Ruppert, et al.
Blood Advances|September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Pageof 5